Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, placebo controlled, parallel group
study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in
patients with advanced stage Parkinson's disease (PD) and dose-dependent motor fluctuations.
Patients (outpatients) will be randomized to one of three different treatment arms.